In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

BD to buy TriPath for $350mm

Executive Summary

Becton Dickinson has offered to pay $9.25 per share (a 58% premium to the pre-announcement market average) to acquire the remaining 93.5% of TriPath Imaging (molecular diagnostics) that it does not already own. The deal is valued at approximately $350mm.
Deal Industry
  • In Vitro Diagnostics
  • In Vitro Diagnostics
    • Cytology
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register